Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression
- PMID: 23001085
- PMCID: PMC4162482
- DOI: 10.1097/SLA.0b013e31826d90bb
Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression
Abstract
Objective: To minimize maintenance immunosuppression in upper-extremity transplantation to favor the risk-benefit balance of this procedure.
Background: Despite favorable outcomes, broad clinical application of reconstructive transplantation is limited by the risks and side effects of multidrug immunosuppression. We present our experience with upper-extremity transplantation under a novel, donor bone marrow (BM) cell-based treatment protocol ("Pittsburgh protocol").
Methods: Between March 2009 and September 2010, 5 patients received a bilateral hand (n = 2), a bilateral hand/forearm (n = 1), or a unilateral (n = 2) hand transplant. Patients were treated with alemtuzumab and methylprednisolone for induction, followed by tacrolimus monotherapy. On day 14, patients received an infusion of donor BM cells isolated from 9 vertebral bodies. Comprehensive follow-up included functional evaluation, imaging, and immunomonitoring.
Results: All patients are maintained on tacrolimus monotherapy with trough levels ranging between 4 and 12 ng/mL. Skin rejections were infrequent and reversible. Patients demonstrated sustained improvements in motor function and sensory return correlating with time after transplantation and level of amputation. Side effects included transient increase in serum creatinine, hyperglycemia managed with oral hypoglycemics, minor wound infection, and hyperuricemia but no infections. Immunomonitoring revealed transient moderate levels of donor-specific antibodies, adequate immunocompetence, and no peripheral blood chimerism. Imaging demonstrated patent vessels with only mild luminal narrowing/occlusion in 1 case. Protocol skin biopsies showed absent or minimal perivascular cellular infiltrates.
Conclusions: Our data suggest that this BM cell-based treatment protocol is safe, is well tolerated, and allows upper-extremity transplantation using low-dose tacrolimus monotherapy.
Trial registration: ClinicalTrials.gov NCT00722280.
Conflict of interest statement
Disclosure: The authors declare no conflicts of interest.
Figures



Similar articles
-
From Auto- to Allotransplantation: Immunomodulatory Protocol for Hand and Arm Transplantation.J Reconstr Microsurg. 2018 Nov;34(9):683-684. doi: 10.1055/s-0038-1651524. Epub 2018 May 18. J Reconstr Microsurg. 2018. PMID: 29775981 Review.
-
Favoring the risk-benefit balance for upper extremity transplantation--the Pittsburgh Protocol.Hand Clin. 2011 Nov;27(4):511-20, ix-x. doi: 10.1016/j.hcl.2011.08.008. Hand Clin. 2011. PMID: 22051391 Review.
-
Experimental short-term immunosuppression after bowel transplantation and donor-specific bone marrow infusion.Arch Surg. 2001 Jul;136(7):817-21. doi: 10.1001/archsurg.136.7.817. Arch Surg. 2001. PMID: 11448397
-
Preliminary experience with alemtuzumab induction therapy combined with maintenance low-dose tacrolimus monotherapy in small-bowel transplantation in China.Transplant Proc. 2010 Jan-Feb;42(1):29-34. doi: 10.1016/j.transproceed.2009.12.028. Transplant Proc. 2010. PMID: 20172275
-
Toward Development of the Delayed Tolerance Induction Protocol for Vascularized Composite Allografts in Nonhuman Primates.Plast Reconstr Surg. 2020 Apr;145(4):757e-768e. doi: 10.1097/PRS.0000000000006676. Plast Reconstr Surg. 2020. PMID: 32221215
Cited by
-
New directions in immunosuppression after heart transplantation.Nat Rev Cardiol. 2013 Jul;10(7):422-7. doi: 10.1038/nrcardio.2013.63. Epub 2013 Apr 30. Nat Rev Cardiol. 2013. PMID: 23629437 Review.
-
Saving face: The search for alternatives to life-long immunosuppression for face transplants.Nat Med. 2016 May 5;22(5):448-9. doi: 10.1038/nm0516-448. Nat Med. 2016. PMID: 27149211 No abstract available.
-
The intragraft vascularized bone marrow induces secondary donor-specific mystacial pad allograft tolerance.Front Immunol. 2022 Dec 12;13:1059271. doi: 10.3389/fimmu.2022.1059271. eCollection 2022. Front Immunol. 2022. PMID: 36578498 Free PMC article.
-
Novel Human Umbilical Di-Chimeric (HUDC) cell therapy for transplantation without life-long immunosuppression.Stem Cell Investig. 2023 Aug 14;10:16. doi: 10.21037/sci-2023-024. eCollection 2023. Stem Cell Investig. 2023. PMID: 37614644 Free PMC article.
-
Outcomes after hand and upper extremity transplantation.J Mater Sci Mater Med. 2017 May;28(5):72. doi: 10.1007/s10856-017-5880-0. Epub 2017 Mar 30. J Mater Sci Mater Med. 2017. PMID: 28361279 Review.
References
-
- Petruzzo P, Lanzetta M, Dubernard JM, et al. The international registry on hand and composite tissue transplantation. Transplantation. 2010;90:1590–1594. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical